5(S)-(Boc-amino)-4(S)-(tert-butyldimethylsilyloxy)-6-phenyl-2(R)-(p-cyanophenylmethyl)-hexanoic acid | 150609-80-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 5(S)-(Boc-amino)-4(S)-(tert-butyldimethylsilyloxy)-6-phenyl-2(R)-(p-cyanophenylmethyl)-hexanoic acid
• 英文别名: 5(S)-(Boc-Amino)-4(S)-(tert-butyldimethylsilyloxy)-6-phenyl-2(R)-[(p-cyano-phenyl)methyl]hexanoic acid；(2R,4S,5S)-4-[tert-butyl(dimethyl)silyl]oxy-2-[(4-cyanophenyl)methyl]-5-[(2-methylpropan-2-yl)oxycarbonylamino]-6-phenylhexanoic acid
• CAS: 150609-80-6
• 化学式: C₃₁H₄₄N₂O₅Si
• 分子量: 552.786
• InChiKey: HUEFCNUWNVEGCP-PVHODMMVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.72
• 重原子数：
  39
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  咪唑 、 5(S)-(Boc-Amino)-4(S)-hydroxy-6-phenyl-2(R)-[(p-cyanophenyl)methyl]hexanoic acid 、 叔丁基二甲基氯硅烷 在 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 5(S)-(Boc-amino)-4(S)-(tert-butyldimethylsilyloxy)-6-phenyl-2(R)-(p-cyanophenylmethyl)-hexanoic acid
  参考文献：
  名称：

  Antiviral ethers of aspartate protease substrate isosteres

  摘要：

  抗逆转录病毒化合物（例如对抗HIV有效）的化学式为I ##STR1## 其中R.sub.1是酰基基团的低烷氧基-低烷酰基，其低烷氧基团未取代或被卤素、苯基、低烷氧基或从哌啶基、吡咯啉基、四氢吡喃基、四氢呋喃基、噻唑啉基、噻唑基、吲哚基或4H-1-苯并吡喃基中选择的杂环基团取代；未取代或被上述未取代或取代的杂环基团之一取代的低烷酰基；被杂环基或杂环基-低烷基取代的芳基酰基或杂环基酰基；被羟基和低烷基取代的苯基-低烷酰基；或芳基磺酰基；或根据描述定义的氨基酸残基（可能在氨基氮上由上述酰基基团之一酰化）；R.sub.2和R.sub.3分别为环己基、环己烯基、苯基、萘基或四氢萘基，未取代或被低烷基、苯基、氰苯基、苯基-低烷基、卤素、卤代低烷基、氰基、羟基、低烷氧基、苯基-低烷氧基、吡啶基-低烷氧基、低烷氧基-低烷氧基、低烷氧基羰基-低烷氧基、羧基-低烷氧基、羟基-低烷氧基、氨基甲酰基-低烷氧基、氰基-低烷氧基和未取代或被卤素取代的苯基-低烷烷基磺酰基取代；R.sub.4为低烷基、环己基或苯基；R.sub.5为低烷基；n为1或2，或其盐，均为新颖的。

  公开号：

  US05663200A1

文献信息

• 5-amino-4-hydroxyhexanoic acid derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05643878A1

  公开（公告）日：1997-07-01

  Compounds of formula I ##STR1## or their hydroxy-protected derivatives, and compounds of formula I' ##STR2## wherein T is an acyl radical of formula Z ##STR3## wherein R.sup.z is unsubstituted or substituted hydrocarbyl wherein at least one carbon atom has been replaced by a hetero atom with the proviso that a hetero atom is not bonded directly to the carbonyl to which the radical R.sup.z is bonded, alkyl having two or more carbon atoms, lower alkenyl, lower alkynyl, aryl or unsubstituted or substituted amino, and wherein the radicals R.sub.1, B.sub.1, R.sub.2, R.sub.3, A.sub.1, A.sub.2 and NR.sub.4 R.sub.5 are as defined in the description, and precursors thereof, are described. The compounds have pharmaceutical activity, for example in the treatment of retroviral diseases, such as AIDS.

  式I的化合物##STR1##或其羟基保护衍生物，以及式I'的化合物##STR2##其中T是式Z的酰基基团##STR3##其中R.sup.z是未取代或取代的烃基，其中至少有一个碳原子被杂原子取代，但杂原子不直接连接到基团R.sup.z所连接的羰基上，烷基具有两个或更多碳原子，低烯烃基，低炔基，芳基或未取代或取代的氨基，其中基团R.sub.1，B.sub.1，R.sub.2，R.sub.3，A.sub.1，A.sub.2和NR.sub.4R.sub.5的定义如描述中所述，并描述了其前体。这些化合物具有药物活性，例如在治疗逆转录病毒性疾病（如艾滋病）方面。
• Antiviral ethers of aspartate protease substrate isosteres
  申请人：Ciba-Geigy Corporation

  公开号：US05663200A1

  公开（公告）日：1997-09-02

  Antiretroviral compounds (which are effective, for example, against HIV) of the formula I ##STR1## in which R.sub.1 is an acyl radical lower-alkoxyl-lower-alkanoyl whose lower alkoxy radical is unsubstituted or is substituted by halogen, phenyl, lower alkoxy or a heterocyclic radical selected from piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolidinyl, thiazolyl, indolyl or 4H-1-benzopyranyl which is unsubstituted or substituted by oxo, hydroxyl, amine, lower alkyl, lower-alkoxycarbonyl and/or phenyl-lower-alkoxycarbonyl; lower alkanoyl which is unsubstituted or is substituted by one of the said unsubstituted or substituted heterocyclic radicals; arylcarbonyl or heterocyclylcarbonyl which are substituted by heterocyclyl or heterocyclyl-lower-alkyl; phenyl-lower-alkanoyl which is substituted by hydroxyl and lower alkyl; or arylsulfonyl; or the residue of an amino acid which is defined in accordance with the description (and which may be acylated on the amino nitrogen by one of the abovementioned acyl radicals); R.sub.2 and R.sub.3 are in each case cyclohexyl, cyclohexenyl, phenyl, naphthyl or tetrahydronaphthyl which are unsubstituted or substituted by lower alkyl, phenyl, cyanophenyl, phenyl-lower-alkyl, halogen, halo-lower-alkyl, cyano, hydroxyl, lower alkoxy, phenyl-lower-alkoxyl, pyridyl-lower-alkoxy, lower-alkoxy-lower-alkoxy, lower-alkoxycarbonyl-lower-alkoxy, carboxyl-lower-alkoxy, hydroxyl-lower-alkoxy, carbamoyl-lower-alkoxy, cyano-lower-alkoxy, and phenyl-lower-alkanesulfonyl which is unsubstituted or substituted by halogen; R.sub.4 is lower alkyl, cyclohexyl or phenyl; and R.sub.5 is lower alkyl; and n is 1 or 2, or salts thereof, are novel.

  抗逆转录病毒化合物（例如对抗HIV有效）的化学式为I ##STR1## 其中R.sub.1是酰基基团的低烷氧基-低烷酰基，其低烷氧基团未取代或被卤素、苯基、低烷氧基或从哌啶基、吡咯啉基、四氢吡喃基、四氢呋喃基、噻唑啉基、噻唑基、吲哚基或4H-1-苯并吡喃基中选择的杂环基团取代；未取代或被上述未取代或取代的杂环基团之一取代的低烷酰基；被杂环基或杂环基-低烷基取代的芳基酰基或杂环基酰基；被羟基和低烷基取代的苯基-低烷酰基；或芳基磺酰基；或根据描述定义的氨基酸残基（可能在氨基氮上由上述酰基基团之一酰化）；R.sub.2和R.sub.3分别为环己基、环己烯基、苯基、萘基或四氢萘基，未取代或被低烷基、苯基、氰苯基、苯基-低烷基、卤素、卤代低烷基、氰基、羟基、低烷氧基、苯基-低烷氧基、吡啶基-低烷氧基、低烷氧基-低烷氧基、低烷氧基羰基-低烷氧基、羧基-低烷氧基、羟基-低烷氧基、氨基甲酰基-低烷氧基、氰基-低烷氧基和未取代或被卤素取代的苯基-低烷烷基磺酰基取代；R.sub.4为低烷基、环己基或苯基；R.sub.5为低烷基；n为1或2，或其盐，均为新颖的。